The here reported in silico experimental workflow finally led to the identification of new mPGES‐1 inhibitors, and further subsequent investigations allowed to disclose their ability to inhibit sEH, thus identifying unprecedented mPGES‐1/sEH dual inhibitors that showed promising anticancer activities against CRC cell lines. Here, EPHX2 is linked to colorectal carcinoma.